Skip to main content

The role of ghrelin signalling in second-generation antipsychotic-induced weight gain

Journal Article


Download full-text (Open Access)

Abstract


  • Based on clinical and animal studies, this review suggests a tri-phasic effect of second-generation antipsychotics (SGAs) on circulating ghrelin levels: an initial increase exerted by the acute effect of SGAs; followed by a secondary decrease possibly due to the negative feedback from the SGA-induced body weight gain or hyperphagia; and a final re-increase to reach the new equilibrium. Moreover, the results can also vary depending on individual SGAs, other hormonal states, dietary choices, and other confounding factors including medical history, co-treatments, age, gender, and ghrelin measurement techniques. Interestingly, rats treated with olanzapine, an SGA with high weight gain liabilities, are associated with increased hypothalamic ghrelin receptor (GHS-R1a) levels. In addition, expressions of downstream ghrelin signalling parameters at the hypothalamus, including neuropeptide Y (NPY)/agouti-related peptide (AgRP) and proopiomelanocortin (POMC) are also altered under SGA treatments. Thus, understanding the role of ghrelin signalling in antipsychotic drug-induced weight gain should offer potential novel pharmacological targets for tackling the obesity side-effect of SGAs and its associated metabolic syndrome.

Publication Date


  • 2013

Citation


  • Zhang, Q., Deng, C. & Huang, X. (2013). The role of ghrelin signalling in second-generation antipsychotic-induced weight gain. Psychoneuroendocrinology, 38 (11), 2423-2438.

Scopus Eid


  • 2-s2.0-84886100577

Ro Full-text Url


  • http://ro.uow.edu.au/cgi/viewcontent.cgi?article=2270&context=smhpapers

Ro Metadata Url


  • http://ro.uow.edu.au/smhpapers/1252

Has Global Citation Frequency


Number Of Pages


  • 15

Start Page


  • 2423

End Page


  • 2438

Volume


  • 38

Issue


  • 11

Place Of Publication


  • United Kingdom

Abstract


  • Based on clinical and animal studies, this review suggests a tri-phasic effect of second-generation antipsychotics (SGAs) on circulating ghrelin levels: an initial increase exerted by the acute effect of SGAs; followed by a secondary decrease possibly due to the negative feedback from the SGA-induced body weight gain or hyperphagia; and a final re-increase to reach the new equilibrium. Moreover, the results can also vary depending on individual SGAs, other hormonal states, dietary choices, and other confounding factors including medical history, co-treatments, age, gender, and ghrelin measurement techniques. Interestingly, rats treated with olanzapine, an SGA with high weight gain liabilities, are associated with increased hypothalamic ghrelin receptor (GHS-R1a) levels. In addition, expressions of downstream ghrelin signalling parameters at the hypothalamus, including neuropeptide Y (NPY)/agouti-related peptide (AgRP) and proopiomelanocortin (POMC) are also altered under SGA treatments. Thus, understanding the role of ghrelin signalling in antipsychotic drug-induced weight gain should offer potential novel pharmacological targets for tackling the obesity side-effect of SGAs and its associated metabolic syndrome.

Publication Date


  • 2013

Citation


  • Zhang, Q., Deng, C. & Huang, X. (2013). The role of ghrelin signalling in second-generation antipsychotic-induced weight gain. Psychoneuroendocrinology, 38 (11), 2423-2438.

Scopus Eid


  • 2-s2.0-84886100577

Ro Full-text Url


  • http://ro.uow.edu.au/cgi/viewcontent.cgi?article=2270&context=smhpapers

Ro Metadata Url


  • http://ro.uow.edu.au/smhpapers/1252

Has Global Citation Frequency


Number Of Pages


  • 15

Start Page


  • 2423

End Page


  • 2438

Volume


  • 38

Issue


  • 11

Place Of Publication


  • United Kingdom